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Andrew L Avins1,2,3*, Daniel C Cherkin4, Karen J Sherman4, Harley Goldberg1 and Alice Pressman1Abstract
Background: Modern clinical-research practice favors placebo controls over usual-care controls whenever a credible
placebo exists. An unrecognized consequence of this preference is that clinicians are more limited in their ability to
provide the benefits of the non-specific healing effects of placebos in clinical practice.
Methods: We examined the issues in choosing between placebo and usual-care controls. We considered why
placebo controls place constraints on clinicians and the trade-offs involved in the choice of control groups.
Results: We find that, for certain studies, investigators should consider usual-care controls, even if an adequate
placebo is available. Employing usual-care controls would be of greatest value for pragmatic trials evaluating
treatments to improve clinical care and for which threats to internal validity can be adequately managed without a
placebo-control condition.
Conclusions: Intentionally choosing usual-care controls, even when a satisfactory placebo exists, would allow
clinicians to capture the value of non-specific therapeutic benefits that are common to all interventions. The result
could be more effective, patient-centered care that makes the best use of both specific and non-specific benefits of
medical interventions.
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Several years ago, a colleague described a patient who
reported that acupuncture was the best treatment she
had found for her chronic low-back pain. Though he
knew that, at the time, most placebo (or ‘sham’)-con-
trolled acupuncture trials did not show a benefit of acu-
puncture relative to placebo, he supported her choice of
therapies. When a colleague challenged him about this
approach, he replied, ‘What am I supposed to tell her?
Don’t get acupuncture? Why would I do that? Of course
I know the whole thing may just be a placebo. Why is
that a problem if she feels better?’
The randomized, double-blind clinical trial has been
the gold standard for studying the efficacy of medical
therapeutics for more than 50 years. For trials without* Correspondence: andrew.avins@ucsf.edu
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reproduction in any medium, provided the oran active comparator, blinding is often achieved by use
of a ‘placebo’, an inert substance or treatment that is in-
distinguishable from the verum treatment but lacks its
active elements. Among other rationales, placebos are ef-
fective in removing from the estimation of treatment ef-
ficacy the placebo effect: the tendency for a patient’s
condition to improve, not through a biologic mechanism
specific to the disease pathophysiology, but because of
‘less-specific’ effects due to the patient’s belief that the
therapy has specific biological effectiveness and the con-
textual effects of the intervention. Subtracting out the
placebo effect from the observed treatment effect per-
mits the estimation of the specific effects of the
intervention.
While the magnitude of the placebo effect is widely
debated [1,2], there is considerable evidence that placebo
effects exist and may be clinically meaningful [2-4]. Nu-
merous direct studies of placebo effects confirm that pla-
cebos can induce physiologic changes that result in
beneficial effects for patients [5,6]. Indeed, Benedetti et
al. showed that at least one compound, proglumide, acts
to augment a placebo analgesic effect but is ineffective intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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greater understanding of the mechanism of placebo
effects evolve, it is likely that there will also be greater
appreciation of both the specific and non-specific effects
of all therapeutic interventions.
The frequent covert use of placebos in clinical practice
attests to the widely held belief among clinicians that
placebos can have important benefits [8,9]. In one recent
survey, nearly half of responding physicians reported
intentionally using placebos, generally in the form of a
medication that the physician believed was ineffective for
the patient’s condition [9]. Most respondents believed
use of placebos did not violate clinical ethics but few ad-
mitted their use to patients.
Though many clinicians value and employ placebo
effects in their practices (generally doing so surrepti-
tiously), current clinical-research paradigms do not ac-
knowledge the potential clinical utility of placebo effects.
Indeed, an intervention that is not superior to placebo is
generally deemed a ‘failure’ even if its placebo effects
provide clinically important benefits for patients.
Since many patients appear to improve when using a
placebo, it would seem desirable to provide them the
benefits of placebos, particularly when the effectiveness
of the best available therapies is limited. However, many
authorities contend that the deliberate use of placebos
runs counter to modern clinical ethics since it requires
deceiving patients by leading them to believe that the
placebo has specific biologic activity that it does not pos-
sess [10-12] (though recent data suggest that deception
might not be essential to eliciting a placebo effect [13];
whether this is generally true remains to be determined).
Thus, because knowingly prescribing a placebo requires
potentially unacceptable deception, clinicians are limited
in their ability to provide their patients with these gener-
ally safe treatments that may yield maximal benefits.
It should be noted that there are many types of trials for
which it is not reasonable or even possible to use placebo
controls. Examples of these include surgical interventions,
behavioral interventions, and conditions for which there is
a standard of care or an effective active drug. While pla-
cebo, or sham, controls are theoretically possible for many
of these trials, ethical or practical considerations limit the
feasibility of conducting such trials. For example, alterna-
tive approaches to case management in mental health care
cannot employ placebo controls. For the purposes of this
discussion, we consider trials for which it is both ethical
and feasible to utilize a placebo control group.
Methods
How use of placebos in research limits their use in clinical
practice
As we demonstrate below, our common use of placebos
in clinical trials may be partly responsible for restrictingour ability to use placebos effectively in clinical practice.
Is there a strategy that would allow us to provide the
advantages of placebo therapy and still allow us to avoid
deception and maintain the critical bond of trust with our
patients? One answer is that it may be time to rethink the
common use of placebos in clinical trials in which the pri-
mary goal is pragmatic: to determine if an intervention is
superior to current standard of care and merits use in clin-
ical practice [14]. Our discussion here refers exclusively to
those conditions for which credible placebos exist and are
commonly employed in clinical trials.
Consider the following hypothetical scenario: clinicians
are interested in a new dietary supplement for the treat-
ment of a symptomatic condition, say, insomnia, for which
the placebo effect is thought to be fairly strong. Further as-
sume that, when added to best-practice usual care, this new
therapy is no more effective than placebo but both are
more effective than usual care alone (Figure 1a).
Two clinician-researchers conduct separate two-arm
randomized clinical trials (RCTs) evaluating the new sup-
plement. Dr Smith’s trial employs a placebo comparison
group and finds no difference between the treatment
arms (Figure 1b); she concludes that the new treatment
is no better than a placebo and rejects its clinical use.
Meanwhile, Dr Jones compares the new supplement to
her usual care alone (that is, no placebo comparison
group, Figure 1c) and finds it superior to usual care. Be-
cause her best evidence is that the new intervention is
better than her current standard of care, she adopts the
new therapy in her clinical practice.
In the end, Dr Smith has conducted a rigorous pla-
cebo-controlled trial that provides strong evidence
against a direct biologic effect of the new therapy. Dr
Jones, on the other hand, has no way of knowing
whether the benefit observed in her study is due to a
specific biologic effect of the intervention, the placebo
effect, or a combination of the two. All she knows is that
the new supplement helps her patients sleep better. How
should informed clinicians respond to these apparently
contradictory results?
Consider a real-life example. Estrada and Young
described a placebo-controlled N-of-1 trial of garlic for
the treatment of hypertension in a patient who was con-
vinced that garlic had helped lower his blood pressure
[15]. During the 6 months he used the garlic supplement,
the patient’s systolic and diastolic blood pressures
declined substantially. To determine if the garlic was re-
sponsible for these changes, the patient and physician
embarked on an N-of-1 trial [16]. The results showed
that only very small reductions in blood pressure could
be attributed to the specific biologic effect of the garlic.
Thus, the benefits observed prior to the trial likely
resulted from non-specific, or placebo, effects (and some



































Figure 1 Response curves for hypothetical clinical trials of a novel medication for insomnia (higher outcome scores represent more
severe sleep problems). (a) three-arm trial with usual-care, placebo, and active-treatment groups; (b) two-arm trial with placebo and active-
treatment groups; (c) two-arm trial with usual-care and active-treatment groups.
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benefits of the garlic supplement had the N-of-1 study
never been performed to determine if the garlic was ‘only
a placebo’.
These examples illustrate that the common preference
for conducting placebo-controlled trials whenever
possible may impair our ability to provide our patients
access to the full range of potential therapeutic benefits,
including non-specific placebo effects. Conducting a
three-arm trial (verum, placebo, and usual-care arms)
does not solve the problem: this design will also make
clear that an intervention is acting primarily through pla-
cebo effects and will tie the hands of clinicians who
might otherwise desire to provide the benefits of a
placebo-like intervention but who cannot do so once the
placebo nature of the intervention becomes apparent. From
a pragmatic viewpoint, the most important question is
whether a new intervention provides better care for
patients than our current standard of practice. Because the
deliberate use of placebos in clinical practice raises ethical
concerns, would it not make more sense to compare a new
therapy to the true clinical alternative (usual care) rather
than to an artificial intervention (placebo) that is not avail-
able to clinicians and patients [17]?
Consider, for example, three-arm RCTs of acupuncture
for painful conditions. Many of these trials show little
difference between real and sham acupuncture, but both
are generally superior to usual care [18,19]. If our clinical
standard is superiority to placebo, then acupuncture
should not be provided for such patients. Such a
position, however, would deprive the benefit of acupunc-
ture to those patients who, by whatever mechanism, find
relief in its use. Unfortunately, we know little about the
persistence of placebo effects over time and further
research is needed to better define the magnitude and
endurance of placebo effects, in order to more rationally
define the proper role for placebo treatments in clinical
medicine.
It may seem that a more measured commitment to
placebo controls would undermine our scientific para-
digm, but such is not the case. For example, suppose we
conduct a clinical trial comparing the combination of
usual care and a test intervention, which we will call
‘obecalp’a, to usual care alone. If this study found the test
intervention superior to usual care (and the results were
subsequently validated), then adding obecalp would be-
come the new standard of care. Under the ethics of clin-
ical trials, future intervention studies for the same
condition would require that obecalp become the control
arm in any test of newer therapeutic possibilities. If the
truth were that obecalp was no more effective than a pla-
cebo (that is, that obecalp was, in fact, only a placebo),
future clinical trials of newer therapeutics for this condi-
tion would simply amount to placebo-controlled trials. Ifnewer therapeutics have specific biologic efficacy in
addition to any non-specific placebo effects, then these
agents would demonstrate superiority over obecalp and
replace it as standard-of-care.
Of course, the discussion to this point presents only
one side of the debate. The choice to employ a usual-
care control group must be made with full recognition of
the advantages of placebo controls and the complexity of
selecting the optimal control condition.
The counter argument: placebos should be used
whenever possible
Placebo controls have become ingrained in clinical
trials because they are effective in controlling several
threats to internal validity. Since no trial with a
substantial risk of bias should serve to guide clinical
practice, promoting validity must take precedence over
whatever clinical benefits may derive from employing
usual-care controls when a credible placebo exists. Be-
yond this affirmation, however, there are serious issues
of risk, commercial self-interest, and trust in clinical
providers to consider.
1. Risks: Suppose a placebo-controlled clinical trial of a
surgical procedure identifies no benefit of surgery
over a sham procedure, but an open-label trial finds
that surgery is superior to usual care (suggesting that
the benefit of the procedure must be primarily
mediated by non-specific effects). For example, such
a condition exists today for the current state of
evidence regarding vertebroplasty for osteoporotic
vertebral compression fractures [20]. Can we justify
putting patients through the risk of anesthesia and
an invasive procedure in order to simply exploit the
placebo effect? Similarly, how would we feel as care
providers should a patient develop a serious side
effect to a medication that was, ultimately, no more
effective than a placebo?
2. Commercial self-interest: Pharmaceutical and device
industries would have great interest in promoting
the use of usual-care controls, as it would increase
the likelihood that such trials would conclude that
some biologically ineffective interventions were
beneficial. Would it be acceptable if companies
profited from marketing products that were, in
essence, placebos?
3. Patient trust in their providers: Modern clinical
practice is expected to be based on sound science,
including biologic plausibility and a firm physiologic
basis. If patients began to believe that the treatments
their provider recommended lacked specific biologic
effects (that is, were placebos), the trust so essential
for a therapeutic patient-provider relationship might
be undermined.
Table 1 Criteria for deciding when to consider a placebo
vs. a usual-care control group
IF THE ANSWER TO ANY ONE OF THESE QUESTIONS IS CLEARLY
‘YES’, USE A PLACEBO CONTROL; IF NOT, CONSIDER THE USE OF A
USUAL-CARE CONTROL CONDITION, EVEN IF A CREDIBLE PLACEBO
EXISTS
1 Is the clinical trial being conducted primarily for explanatory reasons?
2 If the trial is being conducted for both explanatory and pragmatic
reasons, are the explanatory objectives sufficiently important to sacrifice
a potential clinical benefit of a placebo effect?
3 Is the threat of reporting bias so high that there is great danger of
obtaining the wrong answer if a placebo is not used?
4 Is the threat of participant withdrawal so great that it is worth
sacrificing a potential clinical benefit of a placebo effect?
5 Is there a great threat that the use of concomitant or compensatory
therapy may seriously compromise the validity of the trial?
6 Is there a compelling need to study side effects of an intervention and
to know if these side effects are specifically related to the study
intervention?
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use of placebo controls, which has served medical pro-
gress well for many decades. However, there are also
potentially important rewards in a more tempered
approach to placebo controls in clinical research.
A rebuttal to the argument favoring the routine use of
placebo controls
There is understandable discomfort with employing a
usual-care control when a credible placebo exists. How-
ever, concerns about rethinking placebo controls often
derive from the view that the placebo effect is merely a
nuisance parameter that complicates clinical trials and
must be excised through the use of a placebo control. If
placebo effects provide tangible benefits, they, like any
other intervention, should be used when the benefits
outweigh the risks. To patients, ‘non-specific’ positive
effects are indistinguishable from specific positive effects.
If, on average, the benefits to patients outweigh the risks,
why would we withhold a net benefit for patients?
Does this justify the use of an invasive procedure if
patients, on average, feel better postoperatively due to a
placebo effect? There is no simple answer. Most of us
are uncomfortable promoting invasive or potentially
toxic therapies when the benefit is ‘only a placebo’, and
that discomfort should be respected. Indeed, the thera-
peutic bar is legitimately higher if there is a known and
substantial risk, regardless of the mechanism of benefit.
But if, on average, patients are better off with an inter-
vention than without it, we must consider the full bene-
fit/risk trade-off in our therapeutic decision-making if we
are sincere in putting our patients’ interests first. This is
true regardless of who profits from the intervention (as
uncomfortable as that may be), though the specter of fi-
nancial gain should always raise suspicions.
Finally, we know very little about patients’ attitudes to-
ward the use of placebos in clinical practice. But there is
a real possibility that some might feel misled if their pro-
vider knowingly provided a true placebo intervention.
This possibility makes more compelling the imperative
to reconsider the popular inclination to employ placebo
controls. Employing usual-care controls allows clinicians
access to the benefits of the placebo effect without com-
pelling them to knowingly deceive their patients, effect-
ively preserving the patient-provider bond.
That many patients may be relatively unresponsive to
placebos is not a persuasive reason for rejecting treat-
ments whose benefits are largely due to non-specific
effects. Many conventional medical approaches proven
effective in placebo-controlled trials are also of little or
no benefit to many individual patients. Take the case of
statin medications for primary prevention of coronary
heart disease: these medicines have real potential for
harm (including fatal rhabdomyolysis [21]) yet the typicalpatient who takes a statin has only a small chance of
benefit [22]. Why are we so willing to accept the use of a
potentially toxic medication with a specific biologic ef-
fect but so reticent to accept a low-risk intervention
whose benefit is achieved by, as yet, poorly understood
‘non-specific’ mechanisms?
Results and discussion
Toward a balanced view of control-group choice
Choosing an appropriate control group involves a com-
plex set of trade-offs. Depending on the study’s goals and
design, it may be sensible to, at least, consider whether
the reflexive choice of a placebo control is necessarily
the best choice in circumstances in which a placebo
group is possible and ethical. Recognizing the supremacy
of valid research design, we propose a set of questions to
help identify the conditions under which a placebo
control is clearly appropriate (Table 1). If none of the
answers to these questions are strongly affirmative,
specifying a usual-care control should be seriously
contemplated.
The first question addresses the underlying rationale
for the study. If the primary intent is to answer a scien-
tific question about mechanisms (that is, an ‘explanatory
trial’ [14]), then a placebo control would be important
for measuring the specific biologic effects of the inter-
vention (Criterion 1). On the other hand, if the primary
intent is to study the value of an intervention for im-
proving the lives of patients (that is, a ‘pragmatic trial’
[14]), then a usual-care control group may, in some cir-
cumstances, be preferable, as it would incorporate both
biologic and non-specific placebo benefits for patients.
Since many trials have some mix of explanatory and
pragmatic intents, the investigator must weigh the trade-
offs between losing information about mechanism vs.
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the intervention may have for patients (Criterion 2).
Clinical research is vulnerable to measurement and
reporting bias [23]. Disappointment with not receiving
the ‘real’ intervention may color participants’ responses
to outcome assessments and researchers’ belief in the ef-
ficacy of the test treatment may similarly bias their mea-
surements. Blinding participants and observers (for
example, through the use of placebos) effectively controls
reporting bias, though other study design elements can
also help reduce its impact, such as blinding the out-
come-assessment process. However, if the threat of
reporting bias is very great, inclusion of a placebo con-
trol group may be the best option (Criterion 3).
Similarly, participants who were not randomized to
their preferred treatment may be at increased risk of
withdrawing from the study. Effective placebo controls,
which make it difficult or impossible for participants to
know whether they are receiving the verum or control
treatments, can help address this problem (Criterion 4).
However, good study design and practice can also help
mitigate this problem and there are numerous examples
of well-conducted trials with usual-care controls that
maintained high retention rates.
In unblinded studies, investigators may, consciously or
unconsciously, provide particularly attentive care (con-
comitant therapy) in order to enhance the outcomes in
the intervention group and clinicians may do the same
to try to compensate for their patients’ disappointment
with not being assigned to the new treatment (compen-
satory therapy) [24]. Again, placebo controls can do
much to reduce this problem (Criterion 5), although
well-standardized therapies can also prevent such effects
from introducing serious bias.
Finally, misattribution of side effects may occur if par-
ticipants are aware of their study assignment (Criterion
6). While this concern is unlikely to play a dominant role
in decisions about control groups, its importance must
be considered.
The myriad examples of successful, persuasive clinical
trials employing usual-care controls demonstrate that
placebos are not absolutely necessary and that decisions
to use placebo controls should carefully weigh the limita-
tions they impose on clinical care.
Conclusions
The deliberate use of usual-care controls in clinical trials
makes it difficult to know whether an observed treat-
ment benefit is due to specific biologic effects, placebo
effects, or both. The use of usual-care controls, however,
would allow clinicians to ethically provide all forms of
clinical benefits to patients, including those that work
primarily through non-specific placebo effects [25]. Con-
ceivably, in the future, the ethics of medical care mightpermit the clinical use of placebo treatments if adminis-
tered with the intention of benefitting the patient [26].
However, until consensus supporting this practice
emerges, this option remains unavailable.
It is not surprising that placebo controls are so widely
favored in clinical trials given their many advantages.
However, in trials conducted primarily to identify ways
to improve patients’ quality of life, we should reconsider
our instinctive tendency to employ a placebo control
whenever possible [17]. Although a judicious use of
usual-care controls in clinical trials would represent an
uncomfortable departure from a current tenet of re-
search faith, it could allow us to more effectively meet
the needs of our patients.
Endnote
aObecalp, which is simply ‘placebo’ spelled backwards,
has a colorful history as a true placebo used in years
past, often taking the form of ‘sugar pills’ dispensed in
clinic [27].
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